Caxton Associates LP Nektar Therapeutics Transaction History

Caxton Associates LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $424,566 - $895,144	209,146 Added 413.9%	259,677 $586,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $192,660 - $325,747	-63,375 Reduced 55.64%	50,531 $162,000
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $361,082 - $702,800	113,906 New	113,906 $433,000
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $160,271 - $233,488	-10,099 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $170,774 - $366,290	10,099 New	10,099 $184,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.